Investor Relations Contact Us Careers
Nasdaq: FEMY
Fertility Portfolio

The future of fertility care
starts in the OB/GYN office.

As birth rates decline and fertility clinics remain limited, OB/GYNs are critical to expanding access to earlier fertility diagnosis and treatment.

Explore our products Fertility FastTrack™ →
OB/GYN consulting with a patient
The Challenge

Fertility care is too often
delayed, fragmented, and costly.

Millions of women face significant barriers to getting the fertility care they need — long before they ever reach a specialist. The current pathway leaves too many women behind.

~10M
women in the U.S. with infertility¹
~50%
of infertile women never take action²
~1%
of infertile women undergo IVF each year³
  1. 1. https://www.cdc.gov/nchs/nsfg/key_statistics/i-keystat.htm
  2. 2. Nugent CN, Chandra A. Use of fertility services in women ages 20–49 in the United States: 2022–2023. NCHS Data Brief. 2025 Dec;(542):1–10.
  3. 3. Centers for Disease Control and Prevention. 2022 Assisted Reproductive Technology (ART) Fertility Clinic and National Summary Report. US Dept of Health and Human Services, 2024.
Our Solution: Diagnosis FemVue.com →

Diagnose earlier & faster with
hers and his diagnostics.

Diagnosis is a critical first-step in guiding both female patients and their male partners toward treatment.

FemVue In-Office Fallopian Tube Evaluation
SpermVue At-Home Sperm Test
Our Solution: Treatment FemaSeed.com →

Treat sooner in OB/GYNs
office with FemaSeed Complete.

Treatment that enhances natural fertilization and enables women to pursue fertility care sooner through their trusted OB/GYN.

FemSperm Intratubal Insemination (ITI)
FemaSeed Sperm Preparation
Clinical Evidence

Over 2x more effective
than historic IUI.⁴

FemaSeed’s pivotal clinical trial demonstrated compelling efficacy in male-factor infertility with a positive safety profile.

1 in 4 women achieved pregnancy⁴
Pregnancy Rate Per Cycle — FemaSeed® vs. IUI Control
17.5%
FemaSeed® ITI⁴
6.7%
Historical IUI Control⁵
  1. 4. Liu et al. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01–12. doi: 10.33140/JGRM.08.02.08.
  2. 5. Duran et al. (2002). Intrauterine insemination: a systematic review on determinants of success. Human Reproduction, vol.8, no.4, pp.373–384.
Main Menu